KNBIF (Kane Biotech) Change In Payables And Accrued Expense : $0.73 Mil (TTM As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Kane Biotech Change In Payables And Accrued Expense?

Kane Biotech's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2024 was $0.37 Mil. It means Kane Biotech's Accounts Payable & Accrued Expense increased by $0.37 Mil from Jun. 2024 to Sep. 2024 .

Kane Biotech's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $0.15 Mil. It means Kane Biotech's Accounts Payable & Accrued Expense increased by $0.15 Mil from Dec. 2022 to Dec. 2023 .

Kane Biotech Change In Payables And Accrued Expense Historical Data

The historical data trend for Kane Biotech's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kane Biotech Change In Payables And Accrued Expense Chart

Kane Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.25

0.04

0.61

-0.16

0.15

Kane Biotech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.01	0.19	0.21	-0.04	0.37

Kane Biotech Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.73 Mil.

Kane Biotech Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Kane Biotech's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Kane Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kane Biotech Inc (OTCPK:KNBIF) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

KNE:Canada

Address

290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2

Website

https://www.kanebiotech.com

Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.